The company aims to expand its position within advanced wound care by introducing a new silicone foam that will benefit both healthcare professionals and patients. “We are now introducing new ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO. As the company is entering into a new strategy ...

Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

Coloplast is a global leader in specialized intimate healthcare, with strong innovation, high margins, and a defensible moat in core segments. Despite a 20% share price drop, I see upside potential, ...

COPENHAGEN, July 7 (Reuters) - Coloplast (COLOb.CO), opens new tab has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up ...

There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced (PDF) plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products ...

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...

Coloplast (CLPBY) faces operational challenges, with four consecutive top-line misses and reduced growth expectations, but retains a strong core franchise. CLPBY's CEO search remains unresolved, and ...